Skip directly to site content Skip directly to page options Skip directly to A-Z link Skip directly to A-Z link Skip directly to A-Z link

Disclaimer: Early release articles are not considered as final versions. Any changes will be reflected in the online version in the month the article is officially released.

Volume 30, Number 7—July 2024
Research Letter

Plasmodium vivax Infections among Immigrants from China Traveling to the United States

Paloma KhamlyComments to Author , Nahel Kapadia, Minette Umali-Wilcox, Susan M. Butler-Wu, and Kusha Davar
Author affiliations: Los Angeles General Medical Center, Los Angeles, California, USA (P. Khamly, N. Kapadia, M. Umali-Wilcox, S.M. Butler-Wu, K. Davar); Keck School of Medicine of University of Southern California/Los Angeles, Los Angeles (S.M. Butler-Wu)

Main Article

Table

Characteristics and treatment regimens of patients with diagnosed Plasmodium vivax infections among immigrants from China traveling to the United States via Central and South America, Los Angeles, California, USA, January 2023–April 2024*

Case no. Date diagnosed Clinical signs and symptoms Duration of symptoms % Parasitemia Outpatient vs. inpatient Treatment Antirelapse treatment
Case 1
Mar 2023
Fever, chills, myalgias, shortness of breath
2 mo
0.10%
Inpatient
HCQ
Primaquine
Case 2
Mar 2023
Fever, diaphoresis, nausea
1.5 mo
0.30%
Inpatient
AP
Primaquine
Case 3
May 2023
Fever, fatigue, myalgias
9 d
<0.20%
Outpatient
AP
Primaquine
Case 4
Jun 2023
Fever, chills
1 wk
0.13%
Outpatient
Chloroquine
Primaquine
Case 5
Sept 2023
Fever, headache, diarrhea, nausea, vomiting
1 wk
0.05%
Outpatient
AP
Primaquine
Case 6
Jan 2024
Fever, cough
10 d
<0.20%
Outpatient
AP
Primaquine
Case 7
Jan 2024
Fever, chills, myalgias, nausea
10 d
<0.20%
Inpatient
AP
Primaquine
Case 8
Jan 2024
Fever, chills, myalgias
10 d
0.20%–1.0%
Inpatient
AP
Primaquine
Case 9 Jan 2024 Fever, chills, fatigue, cough 4 d 0.20%–1.0% Inpatient Chloroquine Primaquine

*All patients met criteria for uncomplicated malaria. AP, atovaquone/proguanil; HCQ, hydroxychloroquine.

Main Article

Page created: May 02, 2024
Page updated: May 06, 2024
Page reviewed: May 06, 2024
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.
file_external